Clinical considerations in the use of inhalation delivery devices

Journal of Pharmacy Practice

Volumn 14, Issue 4, 2001, Pages 277-295

  Brock, T P ^a   Williams, D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Aerosol; Dry powder inhaler; Inhalation; Metered dose inhaler; Nebulizer

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; FORMOTEROL FUMARATE;

AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DELIVERY SYSTEM; DRY POWDER; HUMAN; INHALATION; METERED DOSE INHALER; NEBULIZER; REVIEW; TREATMENT INDICATION;

EID: 0035212992     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1106/AH8Q-WWE4-QQJ4-PGT5     Document Type: Review

References (111)

1. Consensus conference on aerosols and delivery devices
2. Inhalation delivery of drugs
3. Metered-dose inhaler: Past, present, and future
4. Pharmacokinetics of inhaled drugs
5. Delivery of inhaled medication to children
6. Comparison of infused and inhaled terbutaline in patients with asthma
7. Bioequivalent doses of budesonide and prednisolone in moderate and severe asthma
8. A study of the mechanisms of the anti-asthmatic action of inhaled budesonide
9. Asthma medications and how to use them
10. Aerosol therapy
11. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung
12. Characteristics influencing the effective administration of drugs as inhalation aerosols
13. Principles of nebulizer-delivered drug therapy for asthma
14. Optimizing drug delivery from metered-dose inhalers
15. AARC Clinical Practice Guidelines: Selection of aerosol delivery device
16. Deposition of aerosol in the respiratory tract
17. Aerosol characterization and deposition
18. Deposition and fate of aerosolized drugs
19. Optimal delivery of aerosols from metered-dose inhalers
20. Aerosol therapy for asthma
21. Asthma
22. Aerosols for systemic treatment
23. Aerosol deposition in mechanically ventilated patients: Optimizing nebulizer delivery
24. Albuterol and spacer-induced atrial fibrillation
25. Cardiac toxicity of aerosol propellants
26. Metered-dose inhalers, dry powder inhalers, and transitions
27. Survey of the clinical use of pressurized aerosol inhalers
28. Use and misuse of metered-dose inhalers by patients with chronic lung disease
29. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers
30. Misuse metered-dose inhalers in hospitalized patients
31. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurized metered-dose inhaler
32. Evaluation of conventional press and breathe metered-dose inhaler technique in 501 patients
33. Incorrect use of metered-dose inhalers by medical personnel
34. A comparison of "closed" and "open" mouth techniques of inhalation of a salbutamol metered-dose inhaler
35. Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique
36. How will the Freon ban affect MDIs?
37. Unexpected adverse effects of Freon 11 and Freon 12 as medication propellants
38. Toward international consensus on clinical aerosol administration
39. Aerosol inhalers: Environmentally friendly devices are becoming available
40. Chlorofluorocarbon-free inhalers: Are we ready for the change?
41. A new generation of inhaler technology
42. In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices
43. HFA albuterol has a similar safety profile as CFC albuterol during regular use in asthmatics
44. HFA albuterol provides comparable bronchodilation as CFC albuterol over 12 weeks of regular use in asthmatics
45. Safety of long-term treatment with HFA albuterol
46. Switching patients with asthma from CFC albuterol to HFA albuterol
47. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone
48. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose
49. Hydrofluoroalkane-134a beclomethasone dipropionate 400 mcg is as effective as chlorofluorocarbon beclomethasone dipropionate 800 mcg for the treatment of moderate asthma
50. Extra-fine corticosteroid aerosols from hydrofluoroalkane-134a metered-dose inhalers: Potential advantages and disadvantages
51. Evaluation of aerosol drug output from the OptiChamber and AeroChamber spacers in a model system
52. Choosing the metered-dose inhaler, spacer or holding chamber that matches the patient's need: Evidence that the specific drug being delivered is an important consideration
53. Inhalational drug delivery from seven different spacer devices
54. Effect of multiple actuations, delayed inhalation and antistatic treatment on the bioavailability of salbutamol via a spacer device
55. Delivery of beclomethasone dipropionate from a spacer device: What dose is available for inhalation?
56. Electrostatic charges on plastic spacer devices influences the delivery of salbutamol
57. Reservoir design and dose availability with long-term metered-dose inhaler corticosteroid use
58. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drugs
59. In vitro performance of plastic spacer devices
60. A metal aerosol holding chamber devised for young children with asthma
61. Evaluation of inhalation aids of metered-dose inhalers in asthmatic children
62. The effect of delay, multiple actuations, and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler
63. Metered-dose inhaler accessory devices in acute asthma. Efficacy and comparison with nebulizers; a literature review
64. Bronchodilator delivery in acute airflow obstruction: A meta-analysis
65. Salbutamol treatment of acute severe asthma in the ED: MDI versus handheld nebulizer
66. Efficacy of bronchodilators administered by nebulizers versus spacer devices in infants with acute wheezing
67. The generation of respirable clouds from coarse powder aggregates
68. Comparison of a lactose-free formulation of sodium cromoglycate and sodium cromoglycate plus lactose in the treatment of asthma
69. Evaluation of a breath operated inhaler
70. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurized metered-dose inhaler, as a dry powder and as nebulized solution
71. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects
72. Lung deposition from Turbuhaler is twice that from a pressurized metered-dose inhaler (pMDI)
73. Patients' perception of the Diskus inhaler: A comparison with the Turbuhaler inhaler
74. Peak inspiratory flow rate and inspiratory vital capacity of patients with asthma measured with and without a new dry powder inhaler device (Turbuhaler)
75. Testing of dry powder aerosol formulations in different environmental conditions
76. Patient handling of a multidose dry powder inhalation device for albuterol
77. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines
78. Nebulizers: Principles and performance
79. Comparison of twenty three nebulizer/compressor combinations for domiciliary use
80. Assessment of jet-nebulizers for lung aerosol therapy
81. Evaluation of jet nebulizers for use with gentamicin solution
82. Droplets produced by medical nebulizers
83. Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution
84. Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulizers
85. Fractional deposition from a jet nebulizer: How it differs from a metered-dose inhaler
86. Differences in aerosol output and airways responsiveness between the DeVilbiss 40 and 45 handheld nebulizers
87. A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) Respirator Solution
88. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols
89. Lung deposition from four nebulizers
90. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma: Efficacy and pulmonary deposition
91. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis
92. Deposition mechanics of pharmaceutical particles in human airways
93. Special problems in aerosol delivery: Neonatal and pediatric considerations
94. Handling of a spacer (Babyhaler) for inhalation therapy in 0- to 3-year old children
95. Importance of training for correct Turbuhaler use in preschool children
96. Is the correct use of a dry powder inhaler (Turbuhaler) age dependent?
97. Inhaler use in patients with arthritic hands
98. Practical aspects of drug treatment in elderly patients with mobility problems
99. Systemic activity of inhaled and swallowed beclomethasone dipropionate and the effect of different inhaler devices
100. Issues in the use of inhaled glucocorticoids
101. Systemic bioavailability and potency of high-dose inhaled corticosteroids: A comparison of four inhaler devices and three drugs in healthy adult volunteers
102. The inhalation device influences lung deposition and bronchodilating effect of terbutaline
103. Holding chambers versus nebulizers for beta agonist treatment of acute asthma (Cochrane Review)
104. Assessing costs of aerosol therapy
105. Assessment end points for inhaled drug delivery
106. Assessing metered-dose inhaler technique: Comparison of observation vs. patient self-report
107. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder inhaler device
108. Inhaled drug delivery: A practical guide to prescribing inhaler devices
109. Laryngeal obstruction after inhalation of a penny from a metered-dose inhaler
110. The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes